Scientists Discover Weakness in Deadly Pancreatic Cancer with Experimental Drug

An experimental drug, daraxonrasib, targeting the KRAS protein, has reportedly doubled the survival rate for pancreatic cancer patients, offering new hope for the previously fatal disease.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

index-hrSerbian6d ago

Kako su znanstvenici pronašli slabost jednog od najsmrtonosnijih karcinoma

EKSPERIMENTALNA tableta daraxonrasib, koja cilja na KRAS protein, udvostručila je preživljenje pacijenata s rakom gušterače, nudeći novu nadu u liječenju dosad smrtonosne bolesti.

Read full article →

PERSPECTA

PERSPECTA

Scientists Discover Weakness in Deadly Pancreatic Cancer with Experimental Drug

Sources

Kako su znanstvenici pronašli slabost jednog od najsmrtonosnijih karcinoma

Related Stories

Extreme Training: What Heat Training Does to the Body

1 dead, 95 injured in vehicle crash on Marcos Highway in Benguet

Expert Advice: Clothing as First Defense Against Extreme Heat

Study Shows Radiation Reduces Bladder Cancer Recurrence Risk

PERSPECTA